Pfizer Raises 2026 Forecasts as Eliquis, Cancer Drugs Drive Q3 Beat

Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat

Pfizer raises 2026 forecasts after strong Q3 results

Pfizer has today raised its full-year profit and revenue forecasts as strong demand for its recently acquired cancer drug Padcev and blockbuster blood thinner Eliquis led to higher-than-expected third-quarter results.

Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction

Pfizer's revenue didn't grow, but the mix underneath it changed a lot.

Pfizer Q3 2026 earnings beat estimates, full-year outlook raised

Pfizer raised full-year revenue guidance by $1.5 billion at the midpoint, to a range of $62.0 billion to $64.0 billion

Pfizer Raises 2026 Revenue Forecast to 62-64 Billion

Pfizer beat third-quarter analyst estimates and raised its 2026 revenue and adjusted-earnings forecasts, as growth in several medicines largely offset falling COVID-product and Prevnar sales; investors are also watching cost cuts, upcoming drug exclusivity losses and its obesity pipeline. Its Indian subsidiary reported a sharp quarterly profit increase, driven partly by an exceptional gain from the sale of Minipress XL.

Pfizer lifts 2026 guidance as cancer, migraine sales offset Covid slide

Pfizer raised its 2026 financial guidance as strong growth in its oncology and migraine businesses helped it weather sharp sales drops in its Covid products. The company reported third-quarter sales and ...